Centivax
June 23, 2026
Theater 4
Type: Company Presentation
Focus Area:
Infectious Disease and Vaccines
Centivax is a universal immunity company, deploying a proprietary computational immune-engineering platform to create vaccines and therapies that deliver universal protection against entire classes of diverse targets. The lead clinical candidate for influenza—featured in The New Yorker, the Netflix docuseries Pandemic: How to Prevent an Outbreak, and other outlets—addresses a greater than $7 billion global flu market, with follow-on programs spanning a growing pipeline for Alzheimer's disease, oncology, malaria and a universal antivenom. This growing portfolio underscores the technology's broad potential not only to protect against a wide array of infectious diseases–including viral, bacterial, protozoan, fungal, parasitic and man-made bioterror threats–but also to improve healthspan by reducing the long-term complications these pathogens can trigger, such as neurodegenerative disease, cancer, cardiovascular disease, and autoimmune conditions.
Company HQ City:
South San Francisco
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2001
Lead Product in Development:
Centi-Flu 01, a pan-influenza universal flu vaccine
CEO
Jacob Glanville
Development Phase of Lead Product
Phase I
When you expect your next catalyst update?
July 2026
What is your next catalyst (value inflection) update?
Majority clinical read out of the phase 1A, demonstrating how our vaccine performs against not just the seasonal flu strains, but also pandemic and non-matched strains
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}